News

Date Title and Summary
Toggle Summary Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018
SAN DIEGO --(BUSINESS WIRE)--Oct. 23, 2018-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended
Toggle Summary Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018
SAN DIEGO --(BUSINESS WIRE)--Jul. 30, 2018-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended
Toggle Summary Tesetaxel, Administered Orally as a Single Agent, Results in 45% Confirmed Response Rate in Patients with HER2 Negative, Hormone Receptor Positive, Metastatic Breast Cancer
- Results from Multicenter Phase 2 Study Presented at The 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting - CHICAGO --(BUSINESS WIRE)--Jun. 2, 2018-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that
Toggle Summary Odonate Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
SAN DIEGO --(BUSINESS WIRE)--May 31, 2018-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will present at the Jefferies 2018 Global
Toggle Summary Odonate Therapeutics Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO --(BUSINESS WIRE)--May 16, 2018-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that there will be two poster presentations on
Toggle Summary Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018
SAN DIEGO --(BUSINESS WIRE)--May 3, 2018-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31,
Toggle Summary Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2017
SAN DIEGO --(BUSINESS WIRE)--Feb. 14, 2018-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months
Toggle Summary Odonate Therapeutics Announces Initiation of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Locally Advanced or Metastatic Breast Cancer
SAN DIEGO --(BUSINESS WIRE)--Dec. 28, 2017-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has initiated CONTESSA , a multinational,
Toggle Summary Odonate Therapeutics Announces Closing of Initial Public Offering
SAN DIEGO --(BUSINESS WIRE)--Dec. 11, 2017-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the closing of its initial public offering of
Toggle Summary Odonate Therapeutics Announces Pricing of Initial Public Offering
SAN DIEGO --(BUSINESS WIRE)--Dec. 6, 2017-- Odonate Therapeutics, Inc. (the Company or Odonate), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the pricing of its initial public offering
Back to Top